Potential therapeutic target in AML.PLK1 is overexpressed in AML cases, and high expression is associated with shortened survival [88].A novel oral PLK1 inhibitor (onvansertib) has recently been evaluated for relapsed/refractory AML in a phase Ib trial [89].Onvansertib and decitabine combination is well tolerated and has antileukemic activity particularly in patients with target engagement and decreased mutant circulating tumor DNA (ctDNA) following treatment [89].Complex karyotype AML was reported to display G2/M signature and hypersensitivity to PLK1 inhibition [90]. The gene discussed is PLK1; the disease is neoplasm.